

HEOR Respiratory and Allergy Publications

Conference presentations

Wei W, Ghorayeb E, Andria ML, **Walker V**, et al. A real-world study evaluating AdeQUacy of Existing Systemic Treatments for patients with moderate-to-severe atopic dermatitis (AD-QUEST): baseline treatment patterns and unmet needs assessment. Paper presented at: 2018 Winter Clinical Dermatology Conference - Hawaii; 2018 Jan 12-17; Maui, HI.

Stanford R, **Hull M, Hulbert E, Buikema A**, Reinsch TK, Bogart M. Baseline characteristics and treatment patterns of new users to multiple inhaler triple therapy. Paper presented at: American Thoracic Society 2018 International Conference; 2018 May 18-23; San Diego, CA.

Palli S, **Buikema A, Korrer S**, et al. Comparing healthcare costs in COPD patients initiating tiotropium/olodaterol versus triple therapy. Paper presented at: AMCP 2018 Nexus; 2018 Oct 22-25; Orlando, FL.

Moretz C, Stanford R, Hahn B, Asmus M, **Bengtson L**, et al. Medication adherence to an inhaled fixed dose combination long-acting muscarinic antagonist/long-acting beta-agonist or inhaled corticosteroid/long-acting beta-agonist in patients with COPD within a large US health insurer database. Paper presented at: AMCP 2018 Nexus; 2018 Oct 22-25; Orlando, FL.

Mao J, Davis J, **McPheeters JT**, Xu X, Trung TN. Persistent severe asthma: health care resource utilization and costs for patients receiving multiple controller medications. Paper presented at: 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE); 2018 Aug 22-26; Prague, Czech Republic.

Hahn B, Stanford R, **Goolsby Hunter A, Essoi B, White J, Ray R**. Burden of symptoms among patients with COPD on LAMA monotherapy. Paper presented at: American Thoracic Society 2018 International Conference; 2018 May 18-23; San Diego, CA.

Hahn B, Stanford R, **Goolsby Hunter A, Essoi B, White J, Ray R**. Predictors of disease burden in patients with COPD on LAMA monotherapy. Paper presented at: American Thoracic Society 2018 International Conference; 2018 May 18-23; San Diego, CA.

Bensch G, **Parker ED**, Ariely R, Stoyanov S, Ramakrishnan K. Real-world study characterizing patients prior to receiving albuterol multidose dry powder inhaler or short-acting beta-agonist via pressurized metered-dose inhalers for asthma and COPD in the United States. Paper presented at: 2018 AAAAI/WAO Joint Congress; 2018 Mar 2-5; Orlando, FL.

Bengtson L, Korrer S, Fang Y, Bancroft T, Buikema A. Comparison of healthcare utilization and costs in patients with chronic obstructive pulmonary disease vs asthma-chronic obstructive pulmonary disease overlap syndrome. Paper presented at: American Thoracic Society 2018 International Conference; 2018 May 18-23; San Diego, CA.

Bell CF, **Blauer-Peterson CJ, Mao J**. Burden of illness associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States. Paper presented at: American College of Rheumatology/Association of Rheumatology Health Professional Annual Meeting 2018; 2018 Oct 19-24; Chicago, IL.

Ramakrishnan K, Chipps BE, **Parker ED**, Ariely R, Parikh R, Stoyanov S. Comorbidities associated with poor short-acting beta-agonist inhaler handling among United States respiratory patients. Paper presented at: ACAAI 2017 Annual Scientific Meeting; 2017 Oct 26-30; Boston, MA.

Bengtson LG, McPheeters JT, Fang Y, et al. Impact of chronic obstructive pulmonary disease (COPD) coding differences on health care utilization and cost outcomes for research spanning the ICD-9 to ICD-10 transition. Paper presented at: ISPOR 22nd Annual International Meeting; 2017 May 20-24; Boston, MA.

Averell C, **Johnson P, Essoi B**, Bell C. Evaluating the burden of asthma-related exacerbations: findings from patient and physician online focus groups. Paper presented at: American Thoracic Society 2017 International Conference; 2017 May 19-24; Washington, DC.

Journal articles

- Stanford RH, Bell C, Nag A, **Johnson PT, Johnson MP, Watkins A**. Cross-sectional survey study to examine underuse of twice daily inhaled maintenance therapy among patients with asthma. *J Asthma*. 2018 Nov;5:1-10.
- Wei W, Ghorayeb E, Andria M, **Walker V**, et al. A real-world study evaluating AdeQUacy of Existing Systemic Treatments for patients with moderate-to-severe dermatitis (AD-QUEST):baseline treatment patterns and unmet needs assessment. *SKIN: The Journal of Cutaneous Medicine*. 2018 Feb 23;(2):S1.
- Mao J**, Heithoff KA, **Koep E**, Murphy T, Hammerby E. Cost of subcutaneous immunotherapy in a large insured population in the United States. *Curr Med Res Opin*. 2019 Feb;35(2):351-358. [Epub 2018 Sep 12]
- Hahn B, **Hull M, Blauer-Peterson C, Buikema AR**, Ray R, Stanford RH. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA. *Respir Med*. 2018 Jun;139:65-71.
- Campos MA, Runken MC, Davis AM, **Johnson MP**, Stone GA, **Buikema AR**. Impact of a health management program on healthcare outcomes among patients on augmentation therapy for alpha 1-antitrypsin deficiency: an insurance claims analysis. *Adv Ther*. 2018;35(4):467-481.
- Buikema AR, Brekke L, Anderson A**, et al. The effect of delaying initiation with umeclidinium/vilanterol in patients with COPD: an observational administrative claims database analysis using marginal structural models. *Multidiscip Respir Med*. 2018;13:38.
- Bogart M, Stanford RH, Reinsch T, **Hull M, Buikema A, Hulbert E**. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: a retrospective study. *Respir Med*. 2018 Sep;142:73-80.
- Bengtson LGS**, DePietro M, McPheeters J, Fox KM. Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy. *Ther Adv Respir Dis*. 2018 Jan-Dec;12:1753466618772750.
- Rubin JL, **Thayer S, Watkins A**, Wagener JS, Hodgkins PS, Schechter MS. Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States. *Curr Med Res Opin*. 2017 Apr;33(4):667-674.
- Masseria C, **Martin CK**, Krishnarajah G, **Becker LK, Buikema A**, Tan TQ. Incidence and burden of pertussis among infants less than 1 year of age. *Pediatr Infect Dis J*. 2017 Mar;36(3):e54-e61.
- Bengtson LGS**, Yu Y, Wang W, et al. Inhaled corticosteroid-containing treatment escalation and outcomes for patients with asthma in a U.S. health care organization. *J Manag Care Spec Pharm*. 2017 Nov;23(11):1149-1159.
- Allen-Ramey F, **Mao J, Blauer-Peterson C**, Rock M, Nathan R, Halpern R. Healthcare costs for allergic rhinitis patients on allergy immunotherapy: a retrospective observational study. *Curr Med Res Opin*. 2017 Nov;33(11):2039-2047.
- Shenolikar R, **Mao J, Altan A**. COPD medication adherence and persistence among Medicare enrollees. *Am J Pharm Benefits*. 2016 Feb;8(1):14-21.
- Chastek B, Korrer S**, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. *J Manag Care Spec Pharm*. 2016 Jul;22(7):848-61.
- Mapel DW, Dalal AA, **Johnson PT, Becker LK, Hunter AG**. Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity. *Int J Chron Obstruct Pulmon Dis*. 2015 Jul 30;10:1477-86.
- Mapel DW, Dalal AA, **Johnson P, Becker L, Hunter AG**. A clinical study of COPD severity assessment by primary care physicians and their patients compared with spirometry. *Am J Med*. 2015;128(6):629-637.
- Dang-Tan T, Ismaila A, Zhang S, **Zarotsky V, Bernauer M**. Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review. *BMC Res Notes*. 2015 Sep;8:464.
- Sharafkhaneh A, **Altan AE**, Colice GL, et al. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. *Respir Med*. 2014 Sep;108(9):1310-20.
- Stewart DL, Ryan KJ, **Seare JG, Pinsky B, Becker L**, Frogel M. Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis. *BMC Infect Dis*. 2013 Jul;13:334.
- Sato R, **Gomez Rey G, Nelson S, Pinsky B**. Community-acquired pneumonia episode costs by age and risk in commercially insured US adults aged ≥ 50 years. *Appl Health Econ Health Policy*. 2013 Jun;11(3):251-8.

Stanford RH, **Buikema AR, Riedel AA**, Camargo CA Jr, **Rey GG**, Chapman KR. Asthma controller delay and recurrence risk after an emergency department visit or hospitalization. *Resp Med*. 2012 Dec;106(12):1631-8.

Priest J, **Buikema A, Engel-Nitz NM**, Cook CL, Cantrell CR. Quality of care, health care costs, and utilization among Medicare Part D enrollees with and without low-income subsidy. *Popul Health Manag*. 2012 Apr;15(2):101-12.

Maleki-Yazdi MR, Kelly SM, Lam SY, **Marin M**, Barbeau M, **Walker V**. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. *Can Respir J*. 2012;19(5):319-324.

O'Sullivan AK, Sullivan J, Higuchi K, Montgomery AB. Health care utilization & costs for cystic fibrosis patients with pulmonary infections. *Manag Care*. 2011 Feb;20(2):37-44.

Halpern R, Baker CL, Su J, et al. Outcomes associated with initiation of tiotropium or fluticasone/salmeterol in patients with chronic obstructive pulmonary disease. *Patient Prefer Adherence*. 2011;5:375-88.

Dalal AA, **Liu F, Riedel AA**. Cost trends among commercially insured and Medicare Advantage-insured patients with chronic obstructive pulmonary disease: 2006 through 2009. *Int J Chron Obstruct Pulmon Dis*. 2011;6:533-42.

Stanford RH, **Riedel AA, Johnson JC, Astry CL**. Comparative resource utilization in Medicaid-eligible patients with asthma treated with fixed-dose fluticasone propionate/salmeterol or fluticasone propionate monotherapy. *Clin Ther*. 2010 Sep;32(10):1782-93.

Romero JR, Stewart DL, **Buysman EK**, Fernandes AW, Jafri HS, Mahadevia PJ. Serious early childhood wheezing after respiratory syncytial virus lower respiratory tract illness in preterm infants. *Clin Ther*. 2010 Dec;32(14):2422-32.

Dalal AA, **Christensen L, Liu F, Riedel AA**. Direct costs of chronic obstructive pulmonary disease among managed care patients. *Int J Chron Obstruct Pulmon Dis*. 2010 Oct 5;5:341-9.

Ye X, Gutierrez B, **Zarotsky V, Nelson M**, Blanchette CM. Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured population. *Curr Med Res Opin*. 2009 Sep;25(9):2251-8.

Stanford RH, Fuhlbrigge A, **Riedel A, Rey GG**, Stempel DA. An observational study of fixed dose combination fluticasone propionate/salmeterol or fluticasone propionate alone on asthma-related outcomes. *Curr Med Res Opin*. 2008 Nov;24(11):3141-8.

Darkow T, Chastek BJ, Shah H, Phillips AL. Health care costs among individuals with chronic obstructive pulmonary disease within several large, multi-state employers. *J Occup Environ Med*. 2008 Oct;50(10):1130-8.

Dalal AA, Stanford R, **Henry H, Borah B**. Economic burden of rhinitis in managed care: a retrospective claims data analysis. *Ann Allergy Asthma Immunol*. 2008 Jul;101(1):23-9.

Akazawa M, **Halpern R, Riedel AA**, Stanford RH, Dalal A, Blanchette CM. Economic burden prior to COPD diagnosis: a matched case-control study in the United States. *Respir Med*. 2008 Dec;102(12):1744-52.

Darkow T, Kadlubek PJ, Shah H, Phillips AL, Marton JP. A retrospective analysis of disability and its related costs among employees with chronic obstructive pulmonary disease. *J Occup Environ Med*. 2007 Jan;49(1):22-30.

Stempel DA, **Riedel AA**, Carranza Rosenzweig JR. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. *Curr Med Res Opin*. 2006 Mar;22(3):463-70.

Allen-Ramey FC, Markson LE, **Riedel AA**, Sajjan S, Weiss KB. Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone. *Curr Med Res Opin*. 2006 Aug;22(8):1453-61.

Allen-Ramey FC, Duong PT, **Riedel AA**, Markson LE, Weiss KB. Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline. *Ann Allergy Asthma Immunol*. 2004 Oct;93(4):373-80.